John Chan of the Woolcock Institute gives a presentation during the Pat Burnell session
The second day of DDL 24 opened with a posters on the podium session featuring the finalists for the 2013 Pat Burnell New Investigator Award. The six presenters were:
- Eva Faulhammer, Technical University, Austria: “Effect of Process Parameters and Powder Properties on Low Dose Dosator Capsule Filling”
- Judy Ching-Yee Loo, Faculty of Pharmacy, University of Sydney: “Combination Therapy of Curcumin and Silver Nanoparticles with Enhanced Anti-biofilm Activity for Treatment of Endotracheal Tube-associated Infections”
- Jesslynn Ooi, Woolcock Institute of Medical Research and Discipline of Pharmacology, University of Sydney: “Fluorochemical Mediated Phase Transformations of Beclomethasone Dipropionate”
- John G.Y. Chan, Woolcock Institute of Medical Research and Discipline of Pharmacology, University of Sydney: “An Inhalable Rifapentine Dry Powder Targeting Latent Tuberculosis Infection”
- Daniel Zimarev, University of Cambridge: “Computational Modelling and Stochastic Optimisation of Entrainment Geometries in Dry Powder Inhalers”
- Arcadia Woods, Institute of Pharmaceutical Sciences, King’s College London: “Albumin Nanoparticles for Drug Delivery to the Lungs – In vitro investigation of Biodegradation as a Mechanism of Clearance”
In the next session, “Role of Pharmacokinetics and Pharmacodynamics in developing inhaled products,” Beverley Patterson of Actavis, discussed basics of PK and PD studies; Glyn Taylor of Cardiff University spoke about the relationship between systemic PK and lung PK; and Carsten Ehrhardt of Trinity College Dublin raised questions about the mechanics of absorption in the lung and the role of uptake and efflux transporters.
In the afternoon, Steve Nichols reprised his popular review of the year in OINDPs, this year titled, “What a Difference a Year Makes.” One of the major differences he noted from last year is an improved outlook for OINDPs, with strong growth predicted by many market analysts and a large number of acquisitions and mergers indicating that the industry is in a good position. of new products approved. He suggested that a spate of new product approvals indicates that the asthma/COPD market will undergo a number of changes over the next 5-6 years and that the next year will probably continue to see a significant number of mergers.
